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Abstract
Background: Two contradictory hypotheses have been proposed to explain the relationship
between allergic conditions and malignancies, the immune surveillance hypothesis and the antigenic
stimulation hypothesis. The former advocates that allergic conditions may be protective against
development of cancer, whereas the latter proposes an increased risk. This relationship has been
studied in several case-control studies, but only in a few cohort studies.
Methods: The association between allergic conditions and risk of developing leukemia, Hodgkin's
disease, non-Hodgkin's lymphoma and myeloma was investigated in a cohort of 16,539 Swedish
twins born 1886–1925. Prospectively collected, self-reported information about allergic conditions
such as asthma, hay fever or eczema was obtained through questionnaires administered in 1967.
The cohort was followed 1969–99 and cancer incidence was ascertained from the Swedish Cancer
Registry.
Results: Hives and asthma tended to increase the risk of leukemia (relative risk [RR] = 2.1, 95%
Confidence Interval [CI] 1.0–4.5 and RR = 1.6, 95% CI 0.8–3.5, respectively). There was also an
indication of an increased risk of non-Hodgkin's lymphoma associated with eczema during
childhood (RR = 2.3, 95% CI 1.0–5.3).
Conclusion: In contrast to most previous studies, our results do not indicate a protective effect
of allergic conditions on the risk of developing hematological malignancies. Rather, they suggest that
allergic conditions might increase the risk of some hematological malignancies.
Background
An association between allergic conditions and cancer risk
has been the subject of several epidemiological studies.
Both positive and negative associations have been
observed and two hypotheses have been formulated to
explain such relationships. First, the immune surveillance
hypothesis, which proposes that allergic conditions may
lead to a decreased risk of malignancy by enhancing the
ability of the immune system to detect and eliminate
malignant cells [1]. Evidence from some previous studies
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of hematological malignancies in relation to allergic con-
ditions primarily supports this hypothesis [2-4]. Second,
the antigenic stimulation hypothesis states that immune-
stimulating conditions lead to an increased risk of malig-
nancy, which for hematological malignancies is sup-
ported by some studies [5,6]. This would be caused by a
mechanism where the chronic stimulation induced by the
activated cells of the immune system eventually lead to
randomly occurring pro-oncogenic mutations in actively
dividing cells. There are also a number of studies where no
associations between different allergic conditions and
hematological malignancies were found, or where incon-
sistent results were obtained. It is plausible that the asso-
ciation between allergic conditions and cancer risk is
complex and that the risk of developing cancer could
depend on the specific malignancy and also could be
influenced by the type of allergic condition.
Most previous studies are retrospective case-control stud-
ies. Recall bias may have influenced the results of retro-
spective case-control studies that have asked for past
allergic conditions after diagnosis of malignancy [2-
5,7,8], a problem that partly remains after confirmation of
the information on medical history in medical records [9-
11] and also when a combination of self-reported infor-
mation and information from hospital notes and general
practioner notes was used [12]. There are only a few
cohort studies that have investigated the relationship
between allergic conditions and hematological malignan-
cies [6,13-19]. Four of the studies primarily lend support
to the antigenic stimulation hypothesis for hematological
malignancies, as increased risks, or tendencies toward
increased risks, were found for a history of allergy
[6,15,18,19], whereas two of them support the immune
surveillance hypothesis by showing decreased risks
[16,17]. Four of the studies concerned asthma only
[13,14,16,17].
The purpose of the present study was to investigate the
influence of allergic conditions on the risk of developing
leukemia, malignant lymphoma and myeloma in a well-
established cohort of Swedish twins, and to see whether
the results support the immune surveillance hypothesis or
the antigenic stimulation hypothesis. An important
strength of this study is that information about allergic
conditions and confounding factors has been collected
prospectively, and therefore the exposure is not subject to
differential misclassification.
Methods
The study base consists of a cohort of twins followed by
the Swedish Twin Registry, which was established in 1961
when questionnaires were sent to all 25,778 individuals
in a same-sexed twin pair who were born between 1886
and 1925 and were both living in Sweden in 1961. A
response from both twins in a twin pair was required for
inclusion in the Swedish Twin Registry (21,870 individu-
als) [20]. After 1961 they were followed-up as individuals,
irrespective of their twin-sibling's status. Out of the
responders to the 1961 questionnaire, a new question-
naire was sent to 21,863 eligible subjects in 1963
(response-rate 85.1 %), and in 1967 an additional ques-
tionnaire was sent to 20,576 eligible individuals
(response rate 81.5 %).
The twin cohort was used as a population-based cohort
without considering twin status. The present study
includes the 16,539 individuals (7,167 men and 9,372
women), who responded to the questionnaire mailed in
1967, and who were still alive and not previously diag-
nosed with a hematological malignancy January 1, 1969.
The median follow-up time was 23 years for men and 27
years for women. The median age at baseline was 56 years
(10th and 90th percentiles; 46 and 71 years, respectively).
The cohort was followed from January 1, 1969 until diag-
nosis of a hematological malignancy, death or end of the
study (December 31, 1999), whichever came first. Cancer
incidence and date of death were ascertained by record
linkage to the Swedish Cancer Registry and the Swedish
Cause of Death Registry, respectively. In the Swedish Can-
cer Registry, leukemia is coded according to ICD-8 during
the investigated period, while all other malignancies are
coded according to ICD-7. We identified 324 subjects
with hematological malignancies; 10 cases of HD (ICD-7
201), 112 cases of NHL (ICD-7 200.0–200.3, 202.0–
202.4), 75 cases of myeloma (ICD-7 203) and 134 cases
of leukemia (ICD-8 204.0–207.9). The leukemias consist
of 3 cases of ALL, 67 cases of CLL, 31 cases of AML, 7 cases
of CML and 26 cases of unspecified leukemia.
Exposure assessment
Assessment of exposure is based primarily on the 1967
questionnaire, in which questions were asked about the
allergic conditions asthma, hay fever, eczema and hives,
considering both present and past conditions. The ques-
tions were posed as "Have you ever had asthma? (No/
Yes), "Have you ever had hay fever, rose fever or allergic
rhinitis (characterized by running nose, watery and itch-
ing eyes when you do not have a cold)?" (No/Yes), "Did
you have eczema when you were a baby?" (No/Yes), "Did
you at times later in life have eczema-like skin condi-
tions?" (No/Yes), Do you know the name of the skin
lesion you have or have had? (No/Yes, psoriasis/Yes, hives
(urticaria) allergic rash/Yes, contact eczema/Yes, eczema
in knee or elbow fold/Yes, allergic eczema/Yes, others:
specify name). There were no questions about dates when
symptoms first started or ended, and no information
about treatments used. In the questionnaire from 1963
responses to two questions about asthma and eczema
were included. The subjects could mark if they had hadBMC Public Health 2004, 4:51 http://www.biomedcentral.com/1471-2458/4/51
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asthma or eczema from a list of 17 diseases or the alterna-
tive that they hadn't had any of the given diseases. The
answer from 1963 was used only if a subject had failed to
answer the corresponding question in the 1967 question-
naire. Each medical condition was analyzed separately. In
addition we combined the different conditions in order to
achieve larger numbers of individuals and thereby obtain
more precise results. First, a variable for eczema was cre-
ated, requiring at least one positive answer for childhood
eczema or allergic eczema. Then, a general group of aller-
gic conditions was created, combining the positive
answers for eczemas with positive answers on the ques-
tions of ever having had asthma or hay fever.
Confounders and effect modifiers
All analyses were adjusted for age at enrolment and sex.
We have controlled for confounding from alcohol con-
sumption (g/month), level of education, and smoking
habits (non-smokers, former smokers, current smokers).
Adjustment for these factors did not affect the risk esti-
mates in the majority of analyses, and changed the mag-
nitude of the effect at the most 6% in a few instances.
Therefore, the presented results are only adjusted for age
and sex.
Statistical methods
We estimated the RR and its 95% CI of each hematologi-
cal malignancy through Cox's Proportional Hazards
Model, (SAS program PHREG, SAS Institute, Cary, North
Carolina). To ensure that confidence intervals were not
erroneously narrowed due to dependencies within twin
pairs we performed analyses that adjusted variance esti-
mates for correlated outcomes. We accomplished this
through the use of a SAS macro that stems from the same
theoretical background [21-24] and yields the same
results as the published Fortran program of D.Y. Lin [24].
In simple terms, variance estimates are increased in mag-
nitude proportional to the degree of extra correlation
within twin pairs. Thus, adjusted confidence intervals are
more conservative than unadjusted. If correlations within
twin pairs are not different from what is observed between
unrelated individuals in the cohort with respect to cancer
risk, adjusted and unadjusted variance estimates are iden-
tical. Relative risk estimates are not altered by this
procedure.
Results
Our results showed either increased risks or risks close to
unity for hematological malignancies following allergic
conditions. For leukemia, we found an increased risk
associated with hives, and an indication of elevated risk
associated with asthma, although with wide confidence
intervals (Table 2). For leukemia, excluding CLL, the
increased RR associated with hives was further elevated.
The risk estimates for myeloma were generally close to or
below unity (Table 3). The number of cases with HD was
small, with few exposed cases in all analyses making
results difficult to interpret (data not shown). For NHL,
the risk associated with having had eczema during child-
hood was increased.
Discussion
Our results suggested that allergic conditions are risk fac-
tors for hematological malignancies, and gave support to
the antigenic stimulation hypothesis. Thus, the results are
in concordance with most previous cohort studies
[6,15,18,19].
A major strength of the present cohort study is that infor-
mation about allergic conditions and confounding factors
has been collected prospectively. Therefore the exposure is
not subject to differential misclassification, which is in
contrast to retrospective case-control studies where recall
bias may be a problem [2,3,9] and where separating the
effects of prior allergic conditions from the effect of malig-
nancy per se on the immune system may be difficult. This
study has focused specifically on how allergy influences
the risk of developing hematological malignancies.
Table 1: Self-reported allergic conditions among 16,539 subjects.
Self-reported allergic conditions Number of respondents Number reporting condition % reporting condition
Asthma, Hay fever or Hives 15,168 3,022 19.9
Hay fever 15,546 2,428 15.6
Asthma 16,376 604 3.7
Hives 15,379 430 2.8
Eczema* 14,803 1,033 7.0
Eczema during childhood 14,816 400 2.7
Allergic conditions** 14,294 3,430 24.0
* At least one positive answer for eczema during childhood or allergic eczema.
** At least one positive answer for asthma, hay fever, eczema during childhood or allergic eczema.BMC Public Health 2004, 4:51 http://www.biomedcentral.com/1471-2458/4/51
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Another strength is that the study is based on the Swedish
Twin Registry, which is a unique resource allowing for an
unusually long period of follow-up. In our study, 31 years
of follow-up was possible. The cohort has been followed
continuously in the Population Registry and the Cause of
Death Registry during the study period, and therefore loss
to follow-up is unlikely to be a problem. The Swedish
Twin Registry is considered a study base representative of
the general population of Sweden and has been used in
many epidemiological studies [25-27]. Another strength
is the completeness of the Swedish Cancer Registry, to
which it is required by law to report all incident cancer
cases in Sweden. New cases of cancer are reported by phy-
sicians in hospitals and other establishments as well as by
pathologists. The two independent notifications systems
ensure a high coverage. In addition, we could adjust for
more confounding factors than in previous cohort studies
[6,13-19].
One limitation of the study is the small number of
exposed cases, and therefore random variation cannot be
excluded as an explanation for our findings and for the
same reason no stratification for calendar time was per-
formed. Another limitation in the study is that there may
be non-differential misclassification of the malignancies.
The study period covers 31 years, and during this time
diagnostic practices may have changed. In particular,
some cases previously diagnosed as HD are now likely to
be classified as NHL [28]. This type of error would bias the
effect estimates towards unity.
Differential misclassification of exposure is unlikely as
there is no reason to believe that reporting exposure
should differ between subjects subsequently (years later)
diagnosed with a cancer, and those who are not. Non-dif-
ferential misclassification of exposure is likely to affect the
results, but cannot explain increased risks since it would
dilute the effect estimates towards unity. The allergic con-
ditions are self-reported and not diagnosed by a physi-
cian. However, these self-reported conditions have been
used in an earlier study of brain tumors, where some sup-
port for the postulated hypothesis that allergic conditions
are associated with a decreased risk of developing glioma
was found [29]. Also, the validity of the allergic condi-
tions has been investigated in a group of subjects from the
Swedish Twin Registry [30]. In general, a good agreement
Table 2: Age- and sex-adjusted relative risks for leukemia among subjects with allergic conditions.
Leukemia Leukemia, excluding CLL
Exposure Ne No RR 95% CI Ne No RR 95% CI Ne No RR 95% CI
Asthma, hay fever or hives 31 94 1.4 (0.9–2.1) 21 43 2.0 (1.2–3.4) 10 51 0.8 (0.4–1.6)
Hay fever 21 105 1.1 (0.7–1.8) 14 50 1.5 (0.8–2.8) 7 55 0.7 (0.3–1.6)
Asthma 7 126 1.6 (0.8–3.5) 3 64 1.3 (0.4–4.2) 4 62 1.9 (0.7–5.3)
Hives 7 120 2.1 (1.0–4.5) 6 58 3.6 (1.6–8.5) 1 62 0.6 (0.1–4.3)
Eczema* 8 115 0.9 (0.5–1.9) 3 59 0.7 (0.2–2.2) 5 56 1.2 (0.5–3.1)
Allergic conditions** 30 87 1.1 (0.8–1.7) 18 42 1.4 (0.8–2.4) 12 45 0.9 (0.5–1.7)
Ne = No. of exposed cases, No = No. of unexposed cases.
* At least one positive answer for eczema during childhood or allergic eczema.
** At least one positive answer for asthma, hay fever, eczema during childhood or allergic eczema.
Table 3: Age- and sex-adjusted relative risks for myeloma and non-Hodgkin's lymphoma among subjects with allergic conditions.
Myeloma non-Hodgkin's
Exposure Ne No RR 95% CI Ne No RR 95% CI
Asthma, hay fever or hives 10 58 0.7 (0.4–1.4) 22 83 1.1 (0.7–1.8)
Hay fever 10 62 0.9 (0.5–1.7) 21 87 1.3 (0.8–2.2)
Asthma 07 5 - 01 1 -
Hives 1 67 0.5 (0.1–3.9) 1 10 0.4 (0.0–2.6)
Eczema* 3 67 0.6 (0.2–2.0) 8 87 1.3 (0.6–2.6)
Eczema during childhood 1 69 0.5 (0.1–3.7) 6 89 2.3 (1.0–5.3)
Allergic conditions** 12 55 0.7 (0.4–1.4) 27 69 1.3 (0.8–2.0)
Ne = No. of exposed cases, No = No. of unexposed cases.
* At least one positive answer for eczema during childhood or allergic eczema.
** At least one positive answer for asthma, hay fever, eczema during childhood or allergic eczema.BMC Public Health 2004, 4:51 http://www.biomedcentral.com/1471-2458/4/51
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was found between the self-reported conditions and an
allergologist's diagnosis. Follow-up starts in 1969 and
continues until the end of 1999. During 31 years it is pos-
sible to develop an allergic condition, but these
individuals will still be considered as unexposed members
of the cohort. However, the youngest individuals in our
cohort were 42 years old when the questionnaire was sent
out, which means that this bias have not at all affected
childhood eczema, and hay fever and allergic asthma only
to a small extent, as these conditions usually present ear-
lier in life.
We found an increased risk of NHL among individuals
with eczema during childhood. In the literature, there are
only few studies concerning an association between
eczema and NHL. In one study, a history of eczema was
associated with an increased risk of NHL [10]. In several
studies, elevated risks for different hematological malig-
nancies among persons with eczema have been found, e.g.
[7,11]. On the other hand, eczema has also been observed
to decrease the risk of NHL in two studies [3,9]. Compar-
isons between these other studies and our study are diffi-
cult, however, since the other studies have investigated
general eczema while we have focused on eczema of aller-
gic origin (i.e. allergic eczema and eczema during child-
hood). When using the general definition for eczema
many non-allergic forms will be included and while these
may influence the risk of developing malignancies, the
mechanisms involved are probably different from the
ones active in allergic conditions. Thus, these eczemas are
not included in the present study.
In our material subjects with hives showed an increased
risk of leukemia, especially after exclusion of CLL. Several
other studies have also found an increased risk of AML
[12] and other hematological malignancies associated
with hives [6,9,18]. In contrast, some other studies did
not show this association [8]. A number of studies have
found a protective effect of asthma on the risk of develop-
ing lymphatic leukemia and leukemia, respectively
[16,17]. This relationship between asthma and leukemia
was not confirmed in our study. If anything, our results
support the antigenic stimulation hypothesis. In a recent
cohort study, an increased risk of leukemia was indicated
[19]. On the other hand, most studies of hematological
malignancies in relation to a history of asthma have
shown risks close to unity [8,9].
Clearly, these conflicting results indicate that this area
needs to be investigated further. Allergic conditions, like
asthma and hay fever, are increasing and it is of great
importance to clarify if and how they are connected to
hematological malignancies. The contradictory findings
may have many explanations, e.g. that different immuno-
logical mechanisms may be involved in different types of
asthma, that the pathogenesis is likely to be different even
in seemingly similar hematological malignancies, and
that new forms of pharmacological therapy may influence
not only the outcome of asthma but also the risk of devel-
oping cancer. To solve these problems, large prospective
epidemiological studies on individuals with clinically
strictly defined allergic conditions, including data on
pharmacological treatment and severity of disease, need
to be combined with information about morphologically
defined hematological malignancies, including subtyping
with techniques from modern molecular biology.
Conclusions
In summary, findings from our cohort study suggest that
chronic antigenic stimulation from allergic conditions
might increase the risk of some hematological
malignancies.
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